JP2022529518A5 - - Google Patents

Info

Publication number
JP2022529518A5
JP2022529518A5 JP2021563139A JP2021563139A JP2022529518A5 JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5 JP 2021563139 A JP2021563139 A JP 2021563139A JP 2021563139 A JP2021563139 A JP 2021563139A JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5
Authority
JP
Japan
Application number
JP2021563139A
Other languages
Japanese (ja)
Other versions
JP2022529518A (ja
JP7601788B2 (ja
JPWO2020219904A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029849 external-priority patent/WO2020219904A1/en
Publication of JP2022529518A publication Critical patent/JP2022529518A/ja
Publication of JP2022529518A5 publication Critical patent/JP2022529518A5/ja
Publication of JPWO2020219904A5 publication Critical patent/JPWO2020219904A5/ja
Application granted granted Critical
Publication of JP7601788B2 publication Critical patent/JP7601788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563139A 2019-04-25 2020-04-24 チロシンキナーゼの複素環式阻害剤 Active JP7601788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838696P 2019-04-25 2019-04-25
US62/838,696 2019-04-25
PCT/US2020/029849 WO2020219904A1 (en) 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase

Publications (4)

Publication Number Publication Date
JP2022529518A JP2022529518A (ja) 2022-06-22
JP2022529518A5 true JP2022529518A5 (https=) 2023-05-02
JPWO2020219904A5 JPWO2020219904A5 (https=) 2023-05-02
JP7601788B2 JP7601788B2 (ja) 2024-12-17

Family

ID=72941423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563139A Active JP7601788B2 (ja) 2019-04-25 2020-04-24 チロシンキナーゼの複素環式阻害剤

Country Status (7)

Country Link
US (1) US11365189B2 (https=)
EP (1) EP3962908A4 (https=)
JP (1) JP7601788B2 (https=)
CN (2) CN118852118A (https=)
AU (1) AU2020261423B2 (https=)
CA (1) CA3137901A1 (https=)
WO (1) WO2020219904A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
EP3962908A4 (en) 2019-04-25 2022-10-26 Board of Regents, The University of Texas System HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
US20240246940A1 (en) * 2021-04-22 2024-07-25 Voronoi Inc. Heteroaryl derivative compound and use thereof
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266425A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 3-cyano-quinoline derivatives and uses thereof
JP2024532249A (ja) * 2021-08-24 2024-09-05 アースローシ セラピューティクス,インク. 疾患の処置のためのキナゾリン化合物
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476008C (en) * 2002-03-30 2011-12-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
JP6704422B2 (ja) * 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
JP7036798B2 (ja) * 2016-08-25 2022-03-15 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 キナゾリン誘導体の塩の結晶
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors
EP3962908A4 (en) 2019-04-25 2022-10-26 Board of Regents, The University of Texas System HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022529518A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021014044A2 (https=)
BR102021012107A2 (https=)
BR102021012003A2 (https=)